NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis

Protagonist Therapeutics, Inc. (PTGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PTGX

$145.72

−$3.08 (−2.07%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PTGX with… →

PTGX Key Statistics

As of Sep 4, 2026
Trading
Open
$146.47
Previous Close
$148.80
Day's Range
144.01–147.99
52-Week Range
54.50–160.81
Volume
501.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.79
Valuation
Market Cap
$9.43B
P/E Ratio
141.48
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
33.44
EPS (ttm)Profit attributable to each share over the last twelve months.
1.03
Financials (FY)
Revenue (FY)
$46.02M−89.41%
Net Income (FY)
−$130.15M−147.29%
Profit marginThe share of revenue left as profit after all costs and taxes.
29.40%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.71M
1-Year Return
+144.50%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
671.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PTGX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+66.84%
2025+126.27%
2024+68.34%
2023+110.17%
2022−68.10%
2021+69.64%
2020+185.96%
2019+4.75%
2018−67.64%
2017−5.41%
2016 (partial year)+87.95%

As of September 4, 2026.

PTGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$46.02M−$130.15M−282.8%
2024$434.43M$275.19M63.3%
2023$60.00M−$78.96M−131.6%
2022$26.58M−$127.39M−479.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$46.02M—−$158.13M−$130.15M−282.8%
2024$434.43M—$252.84M$275.19M63.3%
2023$60.00M—−$93.65M−$78.96M−131.6%
2022$26.58M—−$131.37M−$127.39M−479.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PTGX Valuation vs Biotechnology Median

Median of 656 stocks
MetricPTGXBiotechnology medianvs median
P/E141.4812.5711.3x the median
P/S ratio33.4415.26119% above
Profit margin29.40%0.00%29.4 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Protagonist Therapeutics, Inc. (PTGX) carries a market capitalisation of $9.43B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 141 employees.

Over the past 52 weeks the price has ranged from $54.50 to $160.81. The most recent close on file for PTGX is $145.72, dated September 4, 2026. That is −$3.08 (−2.07%) against the previous close. The latest close sits 167.38% above that 52-week low.

Financial Health

In fiscal 2025, Protagonist Therapeutics, Inc. reported revenue of $46.02M. Against the prior fiscal year total of $434.43M, that is a change of −89.41%. The same year closed with a net loss of $130.15M. Profit margin runs at 29.4%. That is 29.4 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 1.03.

Across the 4 fiscal years on file, revenue moves from $26.58M in 2022 to $46.02M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

PTGX trades at a trailing price-to-earnings ratio of 141.48. That is 11.3 times the Biotechnology median of 12.57. Measured against sales, the shares trade at 33.44 times revenue. On price-to-sales that is 119.07% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.79. Annualized volatility over the trailing 10 years is 90.18%. The trailing one-year price return is +144.50%. Across 10 years the annualized return works out at +28.28%.

Growth & Income

No dividend is on file for PTGX.

2026 is still running; the price is +66.84% year to date. Across the complete calendar years on file, 2020 returned +185.96% and 2022 returned −68.10%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Protagonist Therapeutics, Inc. (PTGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Protagonist Therapeutics, Inc. PTGX $9.43B 141.5
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Protagonist Therapeutics, Inc. trades at a P/E of 141.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Visit website →